Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 3, 1998, Pages 345-351

  Mehta, Jawahar L ^a   Chen, Liying ^a   Nichols, Wilmer W ^a   Mattsson, Christer ^b   Gustafsson, David ^b   Saldeen, Tom G P ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Biochemistry   (Sweden)

^c Department of Forensic Medicine ^*  (Sweden)

Author keywords

Melagatran; Platelets; Thrombin inhibition; Thrombus

Indexed keywords

FIBRINOGEN; MELAGATRAN; THROMBIN ANTITHROMBIN COMPLEX; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOG; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOGENESIS;

ADMINISTRATION, ORAL; ANIMALS; ANTITHROMBINS; ARTERIAL OCCLUSIVE DISEASES; AZETIDINES; BENZYLAMINES; CORONARY THROMBOSIS; DOGS; ELECTRIC STIMULATION; FIBRINOGEN; FIBRINOLYTIC AGENTS; GLYCINE; MICROSCOPY, ELECTRON, SCANNING; PARTIAL THROMBOPLASTIN TIME; THROMBIN;

EID: 0031952430     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199803000-00003     Document Type: Article

References (29)

1. Capone G, Wolf NM, Myer B, Meister SG. Frequency of intracoronary filling defects by angiography in angina pectoris at rest. Am J Cardiol 1985;46:403-6.
2. Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986; 315:913-9.
3. Friedman M, Van den Bovenkamp GJ. The pathogenesis of a coronary thrombus. Am J Pathol 1966;48:19-44.
4. Friedman M. The coronary thrombus: its origin and fate. Hum Pathol 1971;2:81-128.
5. Aronson DL, Stevan L, Ball AP, Franza BR Jr. Generation of the combined prothrombin activation peptide (F1.2) during the clotting of blood and plasma. J Clin Invest 1977;60:1410-8.
6. Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin and calcium chelation. Blood 1991;78:423-34.
7. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci U S A 1989;86:3619-23.
8. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
9. Heras M, Chesebro JH, Webster MWI, et al. Hirudin, heparin, and placebo during deep arterial injury in the pig. Circulation 1990; 82:1476-84.
10. Chen LY, Nichols WW, Mattson C, et al. Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator improves thrombolysis. J Pharmacol Exp Ther 1996;277:1276-83.
11. Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR. Prevention of rethrombosis after coronary thrombolysis in chronic canine model. II. Adjunctive therapy with r-hirudin. J Cardiovasc Pharmacol 1994;23:203-11.
12. Uriuda Y, Wang QD, Grip L, Ryden L, Sjöqvist PO, Mattsson C. Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin in a closed-chest porcine model of coronary artery thrombosis. Cardiol Res 1996;32:320-7.
13. The Gusto IIb Investigators. The global use of strategies to open occluded coronary arteries: a comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
14. Grip L, Wallentin L, Delborg M, et al. A low molecular weight specific thrombin inhibitor, inogatran versus heparin in unstable angina [Abstract 2512]. Circulation 1996;94:1-430.
15. Gustafsson D, Antonsson T, Bylund R, et al. Melagatran, a new low molecular weight thrombin inhibitor: effects on thrombin and fibrinolytic enzymes. Thromb Haemost 1998 (in press).
16. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine, a model for in vivo evaluation of anti-thrombotic agents. Thromb Res 1980; 17:841-53.
17. Nicolini FA, Mehta JL, Nichols WW, Saldeen TGP, Grant M. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis. Circulation 1990;81:1115-22.
18. Mehta JL, Nicolini FA, Nichols WW, Saldeen TGP. Concurrent nitroglycerin administration decreases thrombolytic potential of tissue-type plasminogen activator. J Am Coll Cardiol 1991;17: 805-11.
19. Nicolini FA, Nichols WW, Saldeen TGP, Khan S, Mehta JL. Adjunctive therapy with low molecular weight heparin with rt-PA causes sustained reflow in canine coronary thrombosis. Am Heart J 1992;124:280-8.
20. Fitzgerald DJ, Fragetta J, FitzGerald GA. Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. J Clin Invest 1988;82:1708-13.
21. Cook JJ, Holahan MA, Lyle EA, et al. Nonpeptide glycoprotein Ilb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther 1996;278:62-73.
22. Jang IK, Gold HK, Ziskind AA, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79:920-8.
23. Badimon JJ, Weng D, Chesebro JH, Fuster V, Badimon L. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity. Thromb Haemost 1994;71:511-6.
24. Cousins GR, Friedrichs GS, Sudo Y, et al. Effective CVS-1123 prevents coronary artery thrombus in the conscious dog. Circulation 1996;94:1705-12.
25. Prager NE, Torr-Brown SR, Sobel BE, Abendschein DR. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. Circulation 1993;22:296-301.
26. Nicolini FA, Lee P, Rios G, Kottke-Merchant, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low-doses markedly improves thrombolysis. Circulation 1994;89:1802-9.
27. Carr ME, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coagul Fibrinolysis 1995;6:567-73.
28. Bajzar L, Morser J, Nesheim M. TAFI, or plasma carboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996;271:16603-8.
29. Redlitz A. Nocolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity: a role in clot lysis in vivo. Circulation 1996;93:1328-30.